Drawing for V THE PEANUT PATCH

USPTO serial 79178501

V THE PEANUT PATCH

Reviewed by CopyMark Law Group

Reg. 5075732Status 709
Filing date
Status date
Registration date
Nov 8, 2016
Examiner
CARROLL, DORITT
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with V THE PEANUT PATCH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Epicutaneous patches for the treatment of peanut allergies by cutaneous or epicutaneous means; all these products are limited to the treatment of peanut allergiesSECTION 71 - CANCELLED
010Epicutaneous drug delivery patches sold without medication for cutaneous or epicutaneous administration of powdered medicated substances for humans or animals; occlusion patch dispensers for medical purposes sold without medication; instruments using the electrostatic properties of biocompatible media, namely, electrostatic patches to administer powdered medicated substances sold without medication; all these products are limited to the treatment of peanut allergiesSECTION 71 - CANCELLED
042Research in the field of immunotherapy; scientific research relating to the design of methods for epicutaneous desensitization via immunotherapy without prior preparation of the skin other than simple and light cleaning in order to leave the cell structure of the skin intact for others; scientific research in the field of processing and treatment of allergies; scientific research in the field of repeatedly applying allergy treatments to the skin of the patient without prior preparation of the skin other than simple and light cleaning in order to leave the cell structure of the skin intact thus avoiding the transfer of the allergen into the blood; scientific research in the fields of allergies, allergic reactions and allergens; scientific research relating to the design of methods for the treatment of allergies through the combination of immune cells from the skins for others; all these services are limited to the treatment of peanut allergiesSECTION 71 - CANCELLED
044Medical Services by applying a method for desensitising immunotherapy; medical treatment services following the method of desensitizing by immunotherapy using epicutaneous means; medical treatment services using epicutaneous means without prior preparation of the skin (other than simple and light cleaning in order to leave the cell structure of the skin intact); consultancy in the field of desensitization to combat allergies; all these services are limited to the treatment of peanut allergiesSECTION 71 - CANCELLED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 13, 2024ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 15, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED
Feb 18, 2024INNTTOTAL INVALIDATION PROCESSED BY THE IB
Jan 31, 2024INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jan 31, 2024INPCINVALIDATION PROCESSED
Jan 19, 2024INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED
May 19, 2023C71TCANCELLED SECTION 71
Nov 1, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED
Apr 14, 2017OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 1, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB
Mar 6, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB
Mar 6, 2017FIMPFINAL DISPOSITION PROCESSED
Feb 17, 2017ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 8, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 8, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 23, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 3, 2016OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 3, 2016OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 3, 2016NPUBNOTICE OF PUBLICATION
Jul 21, 2016CNEAEXAMINERS AMENDMENT MAILED
Jul 21, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jul 21, 2016XAECEXAMINER'S AMENDMENT ENTERED
Jul 21, 2016CNEAEXAMINERS AMENDMENT -WRITTEN
Jun 27, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jun 25, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 25, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 15, 2016RFNTREFUSAL PROCESSED BY IB
Dec 29, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 29, 2015RFRRREFUSAL PROCESSED BY MPU
Dec 29, 2015MAFRAPPLICATION FILING RECEIPT MAILED
Dec 22, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 21, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 21, 2015DOCKASSIGNED TO EXAMINER
Dec 21, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 17, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance